Rosetta Genomics this week announced that it has signed a deal giving the Italian commercialization rights to its three microRNA-based diagnostics to AXA Diagnostics.

Under the deal, privately held AXA will market in Italy Rosetta's miRview Meso, which differentiates lung cancer from mesothelioma; miRview Mets, which is designed to determine the source of cancers of unknown primary origin; and miRview Squamous, which is designed to differentiate squamous from non-squamous non-small cell lung cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.

Sep
12
Sponsored by
PerkinElmer

This webinar will cover recent advances in the use of CRISPR for generating animal models and cell lines.